Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay.

The publication presents a study investigating the efficacy and safety of a novel therapeutic approach in a specific cancer subtype.

The authors conducted a multi-center clinical trial enrolling patients with advanced disease, assessing:

• Response rates
• Progression-free survival
• Overall survival as primary endpoints

Results demonstrated a statistically significant improvement in clinical outcomes compared to the current standard of care, with a manageable safety profile.

The study supports the potential integration of this new treatment into clinical practice for improved patient management.